Sanofi India Limited

Equities

SANOFI

INE058A01010

Pharmaceuticals

Delayed Bombay S.E. 06:00:52 2024-03-28 am EDT 5-day change 1st Jan Change
8,118 INR +2.06% Intraday chart for Sanofi India Limited +7.60% +0.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee CI
Cipla to Distribute Sanofi's CNS Product Line in India MT
Sanofi India Limited and Emcure Pharmaceuticals Announces Exclusive Distribution Partnership to Broad Broadline Reach of Sanofi's Cardiovascular Brands CI
Transcript : Sanofi India Limited, Q4 2023 Earnings Call, Feb 26, 2024
Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024 CI
Sanofi India Limited Declares Interim Dividend for the Financial Year Ended 31St December, 2023, Payable on or After 20 March, 2024 CI
Sanofi India Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sanofi India Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024 CI
Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa DJ
Trending : Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials DJ
Transcript : Sanofi India Limited, Q3 2023 Earnings Call, Nov 15, 2023
Sanofi India's CFO Steps Down MT
Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director CI
Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Chief Financial Officer, effective November 30, 2023 CI
Sanofi India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel CI
Sanofi India Limited Announces Executive Changes CI
Sanofi India Limited Announces Resignation of Vinita Korti Patil as Senior Legal Director - South Asia, Effective 7 December 2023 CI
Sanofi India Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director CI
Sanofi India Limited Announces Resignation of Annapurna Das as Non-Executive Director and Member of the Audit Committee, Effective 31 July 2023 CI
Sanofi India's Consolidated Profit Declines in Fiscal Q4; Shares Jump 8% MT
Transcript : Sanofi India Limited, Q1 2023 Earnings Call, May 11, 2023
Sanofi India Gets Board Nod for Demerger of Consumer Health Business MT
Chart Sanofi India Limited
More charts
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Quarterly revenue - Rate of surprise